RAN

Across TCGA pan-cancer cohorts, RAN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAN data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RAN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAN expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where RAN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.874	0.423	<.001	58	view →
HNSC	DFS	Tertile	III,IV	0.597	0.893	.001	28	view →
CCRCC	OS	Quartile	III,IV	0.473	0.874	.002	24	view →
COAD	DFS	Median	IV	0.493	0.944	.031	12	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.728	.018	6	view →
PDAC	OS	Quartile	All	0.411	0.606	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAN–LSCC (DFS)

Open the LSCC breakdown →